Public Health: County Durham

Albert Owen Excerpts

Wednesday 12th June 2019 Westminster Hall

[Phil Wilson]

That is absolutely right, and that is an issue that the mental health trust raised. If those issues are picked up in the early years or when someone is still at school, they can be resolved. Leaving them just puts extra strain on the mental health trusts in the area.

I want to end on a positive note. I had some schoolchildren in Parliament yesterday from the primary schools in Ferryhill and Chilton. Cleves Cross Primary School in Ferryhill has a whole host of initiatives around mental health, eating properly and so on. Around the village, it is setting up edible walkways: instead of flower beds, it is planting vegetables, which people can pick when they mature. It is great that schools are coming up with those great initiatives, but if the same thing is to happen in schools across Country Durham, there needs to be central provision from public health services.

For wellbeing, there are initiatives to make sure that children have meals together with their families, and to ensure that if there are problems, other children and friends from school are invited along to share those meals. Such initiatives for those aged seven to 10 bode well for the future, and the public health service in Durham needs to look at them, but they must be funded.

We also need to think about how we develop best practice, so that we see such initiatives not just in Ferryhill and Chilton but in Consett, Barnard Castle, Durham city, Esh Winning and Easington—all over County Durham. There needs to be some strategy. As my right hon. Friend said, we need some kind of audit or impact assessment of what cuts to public health mean to areas like ours. What is the reasoning behind making cuts in Durham, where services are needed, and increasing funding in places such as Surrey and Hertfordshire, where they will not be?

[Albert Owen (in the Chair)]

Order. Before I call Dr Roberta Blackman-Woods, I remind Members that this an hour-long debate. I will call the Front-Bench speakers at 5.25 pm, with five minutes for the Opposition and 10 minutes for the Minister, allowing Mr Jones a couple of minutes to finish the debate.

--- Later in debate ---

[Mrs Sharon Hodgson (Washington and Sunderland West) (Lab)]

It is a pleasure to serve under your chairmanship this afternoon, Mr Owen. I thank my right hon. Friend the Member for North Durham (Mr Jones) for securing this important debate and for his excellent speech. I also thank my hon. Friends the Members for Sedgefield (Phil Wilson) and for City of Durham (Dr Blackman-Woods) for their insightful and powerful contributions.

As I have said many times before, under the Tory-led coalition and the current Conservative Government, public health budgets have been cut by £700 million since 2013, with no financial settlement agreed so far post-2020. As we have heard, that means that vital public health services, such as those for smoking cessation, obesity, sexual health and many more, have been stripped back to the bare minimum. That has consequences: gonorrhoea is at its highest level in 40 years and syphilis at its highest level in 70 years; rates of smoking among pregnant women have risen for the first time on record; and Victorian diseases, such as scarlet fever, whooping cough, malnutrition and gout, have seen a 52% upturn since 2010, with an increase of over 3,000 hospital admissions per year.

Life expectancies are stalling and, in some places, declining, with the north-south divide as wide as ever in terms of health and productivity. For a number of us in this Chamber, it was the north-south divide that drove us into politics; to see it as wide as ever, and not closing, drives us to come to debates such as this one. This is a welcome opportunity to highlight and discuss public health in County Durham.

Overall, health and wellbeing have improved significantly in County Durham, but it still remains worse than the England average. Although it has improved in the north, the rest of the country has also improved, so the gap remains wide. In addition, large health inequalities still remain across County Durham, especially with regard to breastfeeding, babies born to mothers who smoke, childhood obesity and premature deaths. The impact becomes obvious when we look at life expectancy. As we have heard, a child born today in the most deprived areas of County Durham can expect to live between seven and eight years less than one born in the least deprived areas.

With that in mind, it is concerning and shocking that County Durham is the worst affected local authority in England when it comes to cuts to the public health grant. Current predictions suggest that Durham County Council will lose £18 million this year from its public health grants. To put that into perspective—I will repeat the figures we have already heard, because they are more shocking the more times you hear them—this means County Durham will be receiving an £18 million cut to public health budgets but Surrey County Council will receive £14.4 million extra and Hertfordshire County Council will receive a boost of £12.6 million.

What assessment has the Minister made of this funding disparity between councils in the north and south, and the impact that has on health outcomes? Does she agree with me that where there is need, funding should follow? How will the Minister support Durham County Council in delivering vital public health services to those who need them most?

The current grant for County Durham, with a population of 525,000, is £47.4 million, which equates to £90 per head. Does the Minister believe that this is a substantial amount of funding per person to tackle all the public health issues, as well as look at prevention for smoking, alcohol and drug misuse, obesity and weight management? Does she believe that £90 per head is enough to also fund early years services, nutrition and physical activity programmes and support mental health and wellbeing services?

As has already been mentioned, there is a life expectancy gap between the north and south of England: it is clear that money follows higher life expectancies, rather than the other way around—or, indeed, deprivation—as it used to. In County Durham, women have a healthy life expectancy of 59. That is compared with Hertfordshire, where women have a healthy life expectancy of 66, and Surrey, where it is 68.

[Albert Owen (in the Chair)]

To give time for the Minister, can the hon. Lady finish up, please?

[Mrs Hodgson]

Yes, I will. I ask the Minister: when will the Government agree a future funding settlement for public health? I am under the impression that this has been postponed now until after the leadership contest. Local authorities and public health services need to know where they stand. As my right hon. Friend the Member for North Durham said when he opened the debate, we cannot have County Durham or other local authorities being left behind any longer.

Medical Aesthetics Industry: Regulation

Albert Owen Excerpts

Tuesday 14th May 2019 Westminster Hall

[Jim Shannon]

Would the Minister consider making it so that under-18s could not have this treatment?

[Albert Owen (in the Chair)]

Minister, you have less than two minutes.

[Jackie Doyle-Price]

Yes, absolutely. I am committed to bringing forward legislation to do that at the earliest possible opportunity. I would really like to engage with the all-party parliamentary group to see what other conclusions they can bring forward quickly, so that we can make use of that legislation, to strengthen the opportunities to have a meaningful register, and indeed to look at the whole issue of insurance and what we should expect everyone involved in this to do.

I am open to debate, and I am absolutely committed to bringing the age restriction in line with things like tattoos and sunbeds. Frankly, it is ridiculous that there is an age limit for getting on a sunbed but anybody can have poison injected into their face. That is clearly ridiculous, and we need to tackle it.

We will encourage consumers to look at choosing a reputable practitioner and to properly interrogate the person doing the procedure, asking them about the risks. I am pleased that Superdrug, which has moved into this field, is having pre-screening conversations with clients and giving them cooling-off time before embarking on the treatment. I think that is really good practice and is something we could encourage throughout the industry, not least because it encourages practitioners to think about how they engage with their consumers and to properly understand the risks themselves.

We are moving into a new period of regulation of dermal fillers. My hon. Friend the Member for South Leicestershire is quite right that they are completely unregulated at present, but they will become regulated by the Medicines and Healthcare Products Regulatory Agency,[Official Report, 12 June 2019, Vol. 661, c. 5MC.] which will put them on a similar footing to Botox and will mean that they need to be given by the prescriber. He is right to highlight the risk of people being able to delegate that responsibility for prescribing, and again we should look at legislating on that. Clearly we could also ask the regulators of medics to look at that, because, frankly, delegating the responsibility for prescribing does not really seem consistent with patient safety. We need to look at that.

I am fast running out of seconds, so I will conclude by thanking my hon. Friend and all hon. Members for their interest in this subject. I hope that we all continue talking about this, so that we can take action quickly. This is massive area of risk for consumers and we need to take action to fix it.

[Albert Owen (in the Chair)]

I am grateful to both the hon. Member for South Leicestershire (Alberto Costa) and the Minister for taking so many interventions.

Question put and agreed to.

Surgical Mesh Implants

Albert Owen Excerpts

Wednesday 18th October 2017 Westminster Hall

[Albert Owen (in the Chair)]

Before I call Emma Hardy to move the motion, I must tell hon. Members that the list of speakers is over-subscribed. I ask those who wish to speak and are on the list not to make long interventions, which eat into other hon. Members’ time. I may also have to impose a time limit of four minutes for other speakers after Emma Hardy.

--- Later in debate ---

[Several hon. Members rose—]

[Albert Owen (in the Chair)]

Order. I must now impose a time limit of four minutes for each speech.

--- Later in debate ---

[Dr Wollaston]

The hon. Gentleman raises an important point, but many women were not even informed that they had the devices in the first place. Other Members have touched on the fact that because the complications can be late in arising and because of the inadequacy of recording, it is very difficult for women to come forward.

In the brief time available, I would like to mention the yellow card scheme—I will add links on my social media later—which enables women to self-report complications. However, if someone does not know they have had the device fitted they will not report those complications. There is work to raise awareness among GPs of the possibility that symptoms that women present with are related to mesh, to ensure that those women are referred. I welcome the specialist centres that have been set up to treat women who have been so adversely affected by mesh, but if mesh is inserted in the first place, it should absolutely be done in specialist centres.

I do not agree that we should ban mesh, because for some women the symptoms of stress urinary incontinence or prolapse can be life-altering. We should retain it as an option where alternative procedures may create worse outcomes or worse complications, but there must be adequate consultation with women about the risks so that they can weigh them up. I agree with Members who have said they hope that NICE can prioritise the development of more detailed guidance, so that we may have it as soon as possible.

A fundamental absence of data is at the heart of the issue. There has been cavalier practice, and we cannot allow that to continue. The women who have been affected deserve an apology and recognition of the extent of the problem and the delays in recognising and dealing with it. I welcome the findings of the mesh oversight group report, which describes pragmatic and practical recommendations, but clear failings have been allowed to continue for so long. At the heart of those failings is the inadequacy of clinical trials, recording and consent. Finally, we know that the devices are regulated by the European Union. I hope the Minister will comment on how the Government propose to take this issue forward after we leave the European Union. At the heart of it is the need to ensure that the safety of women is prioritised at all times.

[Albert Owen (in the Chair)]

I thank the Chair of the Health Committee.

--- Later in debate ---

[Albert Owen (in the Chair)]

I am grateful to the hon. Gentleman. I want to thank all Back-Bench Members for their co-operation with their interventions and speeches, and for taking such a serious tone on this matter. We will now hear from the Front-Bench spokespersons.

--- Later in debate ---

[Mrs Sharon Hodgson (Washington and Sunderland West) (Lab)]

It is a pleasure to serve under your chairmanship, Mr Owen. I thank my hon. Friend the Member for Kingston upon Hull West and Hessle (Emma Hardy) for securing this very important debate and for her excellent contribution. The Opposition fully support her four asks of the Government.

I commend all other speakers for their thoughtful and passionate contributions, and I thank their constituents who allowed their experiences to be shared with us. I especially want to thank Kath Sansom, who leads the Sling the Mesh campaign, for all her hard work in uniting the women affected by vaginal mesh implants and for raising awareness of the tragic impact that mesh implants have had on so many lives. I also thank other hon. Members who have spoken out about this issue for such a long time—in particular, my hon. Friend the Member for Pontypridd (Owen Smith), who spoke with such knowledge and passion. It was vital that he took part in this debate, and I thank him for everything he has done on the issue.

The experiences we have heard about today are incredibly distressing. I have the utmost sympathy for those suffering because of mesh implants. We are here to stand up for those women, and we seek answers and Government action on their behalf.

Let us start at the beginning, when women are told that the best course of action is to have a mesh implant. They are told that the procedure is quick and cheap, but, as we have heard, the low financial cost of the implants is far outweighed by the huge human cost to those women for the rest of their lives.

The NHS and the MHRA say that the risk of complications is low, at 1% to 3%, but a report by nine leading medics put the risk much higher, at 15%. If leading bodies and medical professionals cannot agree, how can patients be expected to make informed decisions? Health professionals are supposed to outline clearly and explicitly the risks of any operation that a patient is asked to undergo to ensure they can weigh up the risks and benefits for themselves.

As we have heard, the mesh implants are made of the same material as some drinks bottles. They can shrink, twist and curl at the edges. The material can degrade, cut through internal tissues, poke through the vaginal wall and stick to organs, causing pain, incontinence, urinary infections and a loss of sex life. Marriages have been destroyed and people have been left unable to walk, work or even to pick up their young children. Knowing those risks, how many in this Chamber would consent to a mesh implant? It is time to take women’s health and wellbeing seriously. They need to be listened to. Their voices need to be heard and their concerns believed so we can put right this injustice and prevent it from going on any longer.

Since this debate was announced, I have been inundated with emails and tweets telling harrowing stories of how women have been affected by vaginal mesh implants. I am sure everyone in the Chamber has received the same sort of emails. Just last night—very late in the day—I received an email from Sling the Mesh with an attachment containing 210 emails out of the 400 it received following the Minister’s answer to my question during Health questions last week, when she said there is not enough evidence to ban the mesh. Those emails are packed with evidence, and I am very happy to pass them on to the Minister. They all detail how the implants have been life-changing, but unfortunately not for the better.

Julie has had to give up her job as a paramedic, and is now trapped in a world of pain and medication. Kath has lost her passion for mountain biking because it is now impossible to get on the bike. Suzi says that her pain consumes her every day.

Another woman, Tina, also shared her experiences. For four years, she went to her GP and accident and emergency several times with excruciating pain, and was sent from pillar to post. She was told that the pain was due to irritable bowel syndrome, painful bladder syndrome and a slipped disc, and that the mesh implant was absolutely not the problem. After four years of searching for answers, she went private and spoke to a surgeon who finally believed her pleas about her pain and partially removed the mesh. She says that her recovery has been successful and she is no longer in pain, which is excellent, but four years is such a long time to lose. We know that many, many women are unable to go private to end their trauma, but they should not have to do so.

After this debate, there is a lobby of mesh-injured women, which I encourage the Minister to attend. We will be joined by Dr Robert Bendavid, who has flown in overnight from Canada. That shows that this really is a worldwide scandal. Many countries, including our own, are just waking up to the horrors of vaginal mesh. In Australia the Senate is holding an inquiry, and in the US vaginal mesh has been considered a high-risk device for nearly a decade. As we heard, vaginal mesh has been suspended in Scotland since 2014, yet across the border the Government have rejected a ban in England and have failed to empathise with the approximately 8,000 women who have been admitted to hospital with a mesh complication. That is not surprising, considering that just 1,000 mesh admissions have been reported to the MHRA as a mesh-related issue. Surgeons are clearly reluctant to report that mesh is the issue, which lets their patients down and distresses them further.

Our next concern is what the Government are going to do to support women who have had to leave because of the effect of vaginal mesh. Most GPs do not attribute the pain to the mesh, so it is very difficult for those women to claim personal independence payments, disability living allowance or any other benefits. They have to rely on their families’ finances, which is incredibly frustrating and distressing to the victims, especially those whose families are unable to support them. We must also consider the women who are suffering in silence and have not come forward yet because of the intimate nature of the issue. After hearing of the experiences of others, some women may be embarrassed or just too scared to come forward for fear of being dismissed as a hysterical woman.

At Health questions last week, the Minister said that a NICE update on vaginal mesh implants is expected at the beginning of next year—my hon. Friend the Member for Pontypridd also mentioned that—but that is too little, too late for the approximately 200 women who will get a vaginal mesh implant on the NHS between now and then and the thousands of women who have already been affected. One of my constituents reached out to me to say that she is worried because she is due to have that surgery soon, and she asked for my advice. Obviously, we cannot give medical advice, so I told her to watch this debate and speak to a surgeon. If there is a chance that a car or an aircraft could cause harm, it would be immediately recalled while the problem was investigated. Why does the precautionary principle not also apply when the health and wellbeing of thousands of women is in jeopardy?

Last week, the Minister said there was not enough evidence to warrant asking the MHRA to reclassify these procedures, but there was so little evidence to justify beginning them in the first place. What exactly is she waiting for? Given what we have heard today, I hope she will recognise the urgent need for action on this issue and justice for those women. I hope she will take these calls back to the Department of Health and ensure that no more women are subject to the risks of vaginal mesh implants. That is why the Opposition are calling for an urgent public inquiry into the number of women adversely affected by vaginal mesh implants and into why the safety of so many women was disregarded. We urge NHS England and NICE to act immediately to update the guidance and suspend the use of vaginal mesh today. It is our duty to ensure that the failings are understood and corrected so that they never happen again. That should be a matter of urgency for the Minister and the Government, and I trust she will respond positively to these calls.

[Albert Owen (in the Chair)]

I remind the Minister to allow the last word to the mover of the motion.

Contaminated Blood

Albert Owen Excerpts

Tuesday 11th July 2017 Commons Chamber

[Nadhim Zahawi (Stratford-on-Avon) (Con)]

I am very grateful to you, Mr Speaker. May I join colleagues in paying tribute to the hon. Member for Kingston upon Hull North (Diana Johnson) and the work she has done in leading the all-party group, as well to my hon. Friend the Member for Worthing West (Sir Peter Bottomley), who has been a joint chairman of that group?

I have been working with the victims in my constituency since 2011—for the past six years—and I consider myself a new boy when it comes to this particular tragedy and scandal. My right hon. Friend the Member for North East Bedfordshire (Alistair Burt) has spent many hours working tirelessly on behalf of those of his constituents who are victims. I pay tribute to him; I know he wanted to take part in the debate but could not because of Government business.

I thank the Prime Minister for listening to the victims of this extraordinary tragedy and to colleagues in the House, and announcing the inquiry. I acknowledge the Minister’s saying to colleagues that the Government are in listening mode on the inquiry’s terms of reference and that they will put the victims at its heart. That is what the victims would expect, and they will be grateful for it.

Many victims—this is certainly true of my constituent Clare Walton—initially did not want an inquiry; they wanted a settlement instead. I pay tribute to Andy Burnham for his work on this issue, as well as to the journalists the hon. Member for Kingston upon Hull North cited. The new evidence that was uncovered led Clare Walton to change her view, and she is now very much supportive of and looking forward to engaging with the inquiry.

It is important that the inquiry looks into the subsequent treatment of victims and holds the relevant bodies to account. On Clare Walton’s behalf, I have been attempting to communicate with the Macfarlane Trust, which was one of the five charities set up to help the victims. I say “help,” but I have to tell the Minister that in my experience the Macfarlane Trust has done anything but help my constituent. It has behaved in an utterly despicable way. It refuses to meet my constituent or me—I have requested meetings for the past six years, but they always come back with a reason why they cannot meet.

The trustees of the Macfarlane Trust have bullied my constituent and “fed her with scraps”—those are her words—while at the same time having a charge over her property for all this time and making a profit on it. The trust refuses to discuss the future of the charge on her property. The scheme administrator will soon be changed to the NHS business advisory service, so she wants to know what will happen when that change takes place. I hope the Government will take some of these issues away and respond more fully at the appropriate time. The Macfarlane Trust says that it cannot give any more information until it has clarity from the Department of Health about transitional arrangements; Clare really wants that clarity. I hope the Minister will intimate, as his predecessor did, that the Macfarlane Trust is not much longer for this world. I have struggled even to speak to the trust on the phone.

Another of my constituents, Adrian Melson, is particularly concerned about the discretionary payments on which many victims rely. I hope that as the Minister begins to look at the evidence before him he will look closely at making sure that, if discretionary payments have become something much more permanent, they are recognised as such and not treated as discretionary. Under the previous Prime Minister, whom I commend for coming out and wanting to resolve this issue, we promised our constituents that no victim would suffer financially under any compensation structure we put in place.

I shall take Mr Speaker’s eloquent words on board and end there, other than to say that this is not a party political issue: successive Governments have failed the victims. I hope we can now come together and have this inquiry, but we must make sure that there is a clear timeline and a deadline.

[Albert Owen (Ynys Môn) (Lab)]

I congratulate my hon. Friend the Member for Kingston upon Hull North (Diana Johnson) on her leadership on this issue. On the hon. Gentleman’s point about coming together, it is important for this issue to be considered at a UK level, because it predates devolution. It is important that the Minister—I thought he was going to speak second in the debate—works with the devolved Administrations and that any future compensation is provided at a UK level so that there are no second-class citizens in the United Kingdom.

[Nadhim Zahawi]

I think the victims who looked at the Scottish settlement have taken that point on board—that is certainly the case with Adrian Melson—and I am sure that the Government listened to the hon. Gentleman’s view. Let us come together and provide a clear timeline for when the victims can get not only justice but compensation.

--- Later in debate ---

[Mr Dunne]

We will ask the Northern Ireland Office to facilitate discussions with officials and representatives in Northern Ireland.

[Albert Owen]

On the point about devolution made by my right hon. Friend the Member for Delyn (David Hanson), is the Minister telling the House that this is a UK-wide inquiry and that the consultation will take place across the UK, so that there will be equality for people such as Mr and Mrs Hutchinson in my constituency in the outcome of the inquiry?

[Mr Dunne]

The scope of the inquiry will be determined as part of the discussions which, as I have said, will take place over coming weeks and short number of months. Our intention is that the devolved Administrations and their residents will have full access to participation in the inquiry, irrespective of where people live or were infected.

The Government intend to update the House once the discussions are complete, and I encourage colleagues with a specific interest to engage in discussions through the all-party group or other relevant groups. In the meantime, if anyone in the House or outside has any evidence of criminality, they should take that evidence to the police as soon as possible. If anyone has any other evidence that they want the inquiry to consider, I would request that they submit it to the inquiry once it has been established. The Government will write to everyone in receipt of payments from the current schemes to make sure that they all know about today’s announcement and to inform them of next steps.

NHS (Charitable Trusts Etc.) Bill

Albert Owen Excerpts

Friday 6th November 2015 Commons Chamber

[Albert Owen (Ynys Môn) (Lab)]

The extra money going to Great Ormond Street hospital is well appreciated by people across the United Kingdom. However, many children’s charities tell me that there is an issue about drugs, in that more of them need to be made available. The second Bill is about off-patent drugs. Will she support that Bill, because it is hugely important to the very people she is talking about?

[Anne Marie Morris]

The hon. Gentleman raises a very important point about drugs. The Government are absolutely focused on that issue. Far be it from me to take words out of the Minister’s mouth, but I am sure that he may well cover the hon. Gentleman’s comments on drugs in his response. Among other things, the special cancer drugs fund has made a considerable difference to many people suffering from cancer.

On that note, I will carry on talking about this really important piece of legislation, and to explain to hon. Members a little more about the history of the hospital. As I originally stated—[Interruption.] Mr Speaker, you are looking querulous. May I continue?

--- Later in debate ---

[Albert Owen]

I apologise for missing the first 14 minutes of the hon. Gentleman’s short speech. He has discussed copyright law, and I know that he is an expert on company law. Does he have expertise on patent law, and will he stay in the Chamber to debate the next Bill? It would be helpful if he curtailed his speech and brought that expertise to bear on the next Bill so that we could have a proper debate and listen to his eloquent speech.

[Madam Deputy Speaker (Mrs Eleanor Laing)]

Order. Sometimes it is difficult for the occupant of the Chair to work out whether an intervention or part of a speech is in order, but the hon. Gentleman has referred specifically to the next Bill, which is not in order. I caution Mr Rees-Mogg to be careful in his response to the hon. Gentleman, and stick to the Bill. By and by we will come to the next Bill.

--- Later in debate ---

[Antoinette Sandbach]

I am grateful to my hon. Friend for raising that matter. He will be aware of the extensive issues at the Betsi Cadwaladr University Health Board, where at times there have been appointments that could be characterised as highly political. Indeed, an individual described as “the axeman” was recently appointed. Given the threat to maternity services at the hospital—my hon. Friend the Member for Vale of Clwyd (Dr Davies) and I have campaigned for them to be retained—I am well aware of those concerns.

[Albert Owen]

The hon. Lady is right to point to Alder Hey’s excellent record. It covers north Wales and my constituency, so I have been there on many occasions. There are trustees from Wales on English hospital boards, and the difficulty with recent legislation is that we do not know whether their role will continue. Welsh trustees on English boards and their Members of Parliament will have difficulty in future. Is she as concerned as I am about that, and does she agree that we need further clarification?

[Antoinette Sandbach]

I am grateful to the hon. Gentleman for raising that point, because one issue with the service reorganisation in north Wales is that the new SuRNICC centre—the sub-regional neonatal intensive care centre—has not yet been built. It was due to be completed by next March, but the first sod has not even been dug out of the ground. Instead, because of the threat to maternity services in north Wales, very sick babies are having to travel over the border to Leighton hospital in Cheshire in order to access the services they need.

The wonderful thing about an independent charity is that, when it comes to appointing trustees, there are no limitations based on where they live or anything of that nature. Trustees should be independent, free-thinking, able to provide good advice and genuinely committed to the charity for which they act, as they have heavy legal responsibilities. I certainly do not imagine that there would be any discrimination on the basis of nationality.

[Albert Owen]

The point I was making is that under English votes for English laws, Welsh Members of Parliament with constituents who are trustees on English boards will not be allowed to vote on legislation affecting them. It might be a technical point, but it is hugely important to my constituents.

[Antoinette Sandbach]

I am so grateful to the hon. Gentleman for making that point, because health services that my constituents access are affected by decisions taken in Wales. The threat to maternity services in north Wales will have a direct impact on the resources of the county of Cheshire and Leighton hospital, yet they have no say in those decisions—even the hon. Gentleman has no say—because they are taken in Cardiff.

Off-patent Drugs Bill

Albert Owen Excerpts

Friday 6th November 2015 Commons Chamber

[Nick Thomas-Symonds]

I agree entirely with my hon. Friend. Twelve medical research charities back the Bill; the NHS clinical commissioners in England back the Bill; and the British Medical Association backs the Bill. More than 10,000 members of the public have written to their MP in support of it. That is in addition to the 20,000 who wrote last year to the former Member for Cardiff North. Four of the medical royal colleges support the Bill. Forty eminent clinicians wrote in recent weeks to The Daily Telegraph to support the Bill. It has incredibly wide support across parties and among the professions.

[Albert Owen (Ynys Môn) (Lab)]

I congratulate my hon. Friend on the Bill and pay tribute to Jonathan Evans, a thoughtful Member of Parliament who introduced a Bill in the previous Parliament. In addition to the long list of experts that my hon. Friend has quoted, I am sure he has had other lobbying letters. I had one from a multiple sclerosis sufferer. He eloquently put his case and said: “Please be there to give us hope.” Does my hon. Friend agree that the Bill will give us hope for cures for the future?

[Nick Thomas-Symonds]

I agree entirely with my hon. Friend.

--- Later in debate ---

[Albert Owen (Ynys Môn) (Lab)]

It is seriously a great pleasure to follow the speeches made not only by the hon. Member for Bury St Edmunds (Jo Churchill), but by the hon. Members for Yeovil (Marcus Fysh) and for Central Ayrshire (Dr Whitford), who brought great expertise to the debate early on. I congratulate my hon. Friend the Member for Torfaen (Nick Thomas-Symonds) on introducing the Bill. In his short time in the House is already gaining his predecessor’s reputation of being well respected across the Chamber.

I pay tribute to the former Member for Cardiff North, Jonathan Evans, who pushed this proposal through with great vigour during the last Parliament. Unfortunately, it fell on deaf ears in the Government. I hope this time that this sensible Bill, proposed by a sensible Member and spoken to by sensible Members in their speeches and interventions, will get a sensible response from the Minister. I know him to be a decent man, and he will do the decent thing.

This is the shortest speech that I will make in the House without a time limit on speeches, because the Bill is hugely important. The details discussed by the hon. Member for Central Ayrshire and others need to be dealt with in Committee. Therefore, we need today, on this Friday afternoon, in a time-limited debate, to get the Bill into that Committee, so that many Members on both sides of the House can speak with passion and knowledge to get the right result for our constituents.

I never speak in the House about personal circumstances, but my wife had a brain tumour in 2002. It was non-malignant and she has made a near-full recovery, but she had major surgery and it impacted on the life of our family, and there are many families like ours. The Bill could afford the release of certain drugs that could shrink such tumours in the future and that could help people in that position. Members of my family have had Parkinson’s, MS and other prolonged conditions. They have lobbied me today to say that the Bill provides hope for them, for their families and for the future.

So that is why I hope that the Minister is really listening to the debate and that he will assist us to get the Bill into Committee, where it deserves to be. Our constituents deserve it to be there. I support its Second Reading, and I hope that Members across the House will also do so. I await the Minister coming along with us, to make a difference to lives, to make intervention real and to make it the right thing to do.

--- Later in debate ---

[The Minister for Community and Social Care (Alistair Burt)]

I thank the hon. Member for Torfaen (Nick Thomas-Symonds) for the way in which he introduced a Bill brought forward last year by my good friend Jonathan Evans. I thank all the right hon. and hon. Members who have made a contribution today.

The Government are in a difficult position. To take a position contrary to that of a breast cancer charity or a number of charities, and to resist action requested by a number of right hon. and hon. Members who speak with knowledge and passion, the Government must be pretty sure of their position and their actions. The hon. Gentleman has had a meeting with the Under-Secretary of State for Life Sciences, my hon. Friend the Member for Mid Norfolk (George Freeman), the charity and others, and he knows that the Government still do not support the Bill. I will defend that position.

No sensible Government would seek to resist people having access to drugs in any way. The reason for resisting what is proposed is that the Government believe that there is another pathway. However, I am also persuaded by what I have heard today and feel sufficiently uncomfortable about the current situation to know that this is not an end of the matter. I will resist the Bill today, but my advice to colleagues in the Department of Health will certainly reflect the mood of the House and what has been said.

[Albert Owen]

I am disappointed by what we have heard so far from the Minister. If he will not listen to me, will he listen to his hon. Friends on the Government Benches who have made a plea for the Bill to go through to Committee? He talks about difficult decisions, and the Prime Minister and his colleagues have been at the Dispatch Box saying that there are difficult decisions to take. I ask the Minister to take a difficult decision by doing a U-turn and supporting the Bill.

[Alistair Burt]

The difficult decision is to stick to the position that I believe to be correct. The onus is on me to explain why, in the face of the debate, I believe the Government’s position is right, and that is what I intend to do. I want to be very upfront about the situation. I have heard the debate very loudly, from colleagues on both sides of the House, and I have heard nothing that is not deeply felt and passionate. It is not always the case that something brought forward by a charity, and indeed advocated passionately by colleagues, is the answer. The difficult decision in government is often to say, “That is not the answer; this is the way forward.” We have all been in that position. I also understand the degree of concern about this—I listened carefully to the hon. Member for Central Ayrshire (Dr Whitford)—and I want to reflect on it.

In the time available before half-past 2—and I make it very clear that I will talk until then, because that is the procedure here—[Interruption.] Well, that is what I am following. In the time available I want to explain why the Government think that what is available to people now is access to the drugs. The most important message that I want to come out of this debate is not that drugs are not available, which I think is highly dangerous, but that treatment is available. If the message that comes out of this debate is that there is only one way forward for people, then there is only one way forward for hope, as colleagues have said, and that is through the Bill. I do not believe that is correct. If it stops anyone from seeking treatment because they think that doctors cannot or will not provide off-label, I think that is wrong. That is what I will set out, because that is the evidence we have.

--- Later in debate ---

[Alistair Burt]

No, I will not on this occasion, because I have taken every intervention since I stood up and I cannot do my job unless I explain what people are concerned about.

As the Government promised when similar measures were discussed in the House this time last year, we held a round-table discussion bringing together some of the key stakeholders. We looked at what action short of legislation the Government could take.

[Albert Owen]

On a point of order, Madam Deputy Speaker, the Minister said earlier that, according to the procedure of this House, he is able to speak until 2.30 pm. I think that is incorrect. Can you give me some guidance? If the Minister sat down one minute before 2.30 pm, would my hon. Friend the Member for Torfaen (Nick Thomas-Symonds) be able to put the question so that we can have a vote and the democratic will of this House can be heard?

[Madam Deputy Speaker (Natascha Engel)]

The hon. Gentleman is absolutely right. That is not procedure, but it is the choice of the Front Bencher how long they speak for. He has put it on the record.

--- Later in debate ---

[Madam Deputy Speaker (Natascha Engel)]

As I said previously, I am not prepared to accept that the Question be now put.

[Albert Owen]

Further to that point of order, Madam Deputy Speaker. The Minister has definitely run out of arguments and he has indicated that he wants us to run out of time. What help and support can you give us to have a closure motion, so that Members who have stayed here today at the request of their constituents can have their names put on the record?

[Madam Deputy Speaker]

Two closure motions have now been moved and twice I have said that I am not prepared to accept them. I am afraid that is just how it is.

Contaminated Blood Products

Albert Owen Excerpts

Wednesday 9th September 2015 Westminster Hall

[Ms Margaret Ritchie (South Down) (SDLP)]

I beg to move,

That this House has considered contaminated blood products.

I am delighted to serve under your chairmanship Mr Owen. I am also pleased that the Under-Secretary of State for Health, the hon. Member for Battersea (Jane Ellison), is here to respond to the debate.

To set the context—[Interruption.]

[Albert Owen (in the Chair)]

Order. Could those leaving the Chamber please do so quickly and quietly?

[Ms Ritchie]

Thank you, Mr Owen.

To set the context for this debate, it is my duty and responsibility to acknowledge the very good work of the all-party group on haemophilia and contaminated blood. One of the joint chairs of the group, my hon. Friend the Member for Kingston upon Hull North (Diana Johnson), is here today for this debate. The all-party group published its report on contaminated blood products in January and clearly outlined the requirements of Government in respect of this very vexatious issue.

I secured this debate to highlight the cause of the victims of contaminated blood and blood products, in particular my constituent, Brian Carberry, a haemophiliac from Downpatrick in South Down. Along with all the other victims, he has waited too long for truth and an acknowledgement that the Government, through the Department of Health, imported such contaminated blood products from the USA in the 1970s and 1980s. The victims have waited a long time for proper compensation and access to drugs that are currently being assessed by the National Institute for Health and Care Excellence, and they need those drugs before stage 2 of the illness, which causes liver dysfunction, sets in.

I hope the Minister can today provide a detailed outline of how she will address this issue once and for all. Two thousand people touched by this tragedy have already died, and that number is rising, as people die waiting for the Government to make a final determination. I urge the Minister today to bring this prolonged delay to an abrupt close with a programme of action, including a commencement date for the consultation, which was announced back on 17 July, and the moneys to help those who have endured endless pain, suffering and anxiety for so many years.

In the ’70s and ’80s, around 7,500 people were infected with hepatitis C or HIV as a result of treatment with blood products provided by the NHS. Many of those people were being treated for haemophilia. Those viruses did not just transform their own lives; their families’ lives were also turned upside down, and some of them, including my constituent, can no longer work.

The several thousand people treated with contaminated blood and blood products by the NHS have been denied the real financial security, and the health and social care that they need. The support currently in place is only partial and does not offer the full and final settlement that those affected and their families need to live with dignity, and it falls far below the equivalent compensation in the Republic of Ireland. The development in support, financial and otherwise, over the years has been haphazard and has been delivered much too slowly. Contaminated blood victims already face substantial financial demands because of the nature of their infections and the inadequacy of their financial compensation.

One lady suffering from the infusion of contaminated blood products told me last week that some sufferers are denied even the basic stage 1 payments, even though they have a weakened and compromised immune system, and suffer chronic fatigue, fibromyalgia, depression and unexplained rashes, with a potential link to breast cancer for women. This lady also had an ileostomy, as her bowel burst, and she had a stillborn child, with all the attendant trauma attached to such an incident. Unlike other contaminated blood patients, she has been denied stage 1 Skipton fund payments. Needless to say, she did not receive the Caxton payments either.

--- Later in debate ---

[Drew Hendry (Inverness, Nairn, Badenoch and Strathspey) (SNP)]

I thank the hon. Lady for taking my intervention, and I congratulate her on securing this important debate. I am here on behalf of several of my constituents, particularly Andy Gunn, whose whole life has been blighted by this unimaginable injustice. Despite several promises that we should expect a comprehensive Government response to the report of the Penrose inquiry, we have heard nothing regarding the time scale. Does she agree that the Government must take immediate action to rectify that?

[Albert Owen (in the Chair)]

Before the hon. Lady carries on, let me say that I understand that Members here have individual constituency cases, but this is a 30-minute debate and I want the Member who secured it to make her case as concisely as she can in the time given, and I want the Minister to have the time to respond. The hon. Lady will also have a couple of minutes at the end of the debate to sum up. Let us see how we go; I am sure that the Minister will be generous with her time.

[Ms Ritchie]

Thank you, Mr Owen, and I also thank the hon. Member for Inverness, Nairn, Badenoch and Strathspey (Drew Hendry) for his intervention, which captured the crux of the problem. We want a full and final settlement for these people, accompanied by drugs for them, because they have suffered immeasurable and unimaginable pain and grief.

It is interesting what Professor Cash—a former president of the Royal College of Physicians and a former director of the transfusion service—has said. He asserts that the Inquiries Act 2005, which defines the parameters of public inquiries, enabled the executives responsible to avoid giving evidence. Apparently, the Act meant that there was a whole area that he could not address, and that is an area worthy of further investigation. I hope that the Government will not fall short in relation to that.

The Haemophilia Society was also critical of the Penrose inquiry report, saying that there had been systemic failures in public health and public oversight. Furthermore, we know that Lord Prior of Brampton made a statement to the House of Lords on Friday 17 July, which was reaffirmed in the Commons on Monday 20 July, when my hon. Friend the Member for Kingston upon Hull North asked her urgent question. However, so far neither Parliament nor the wider public, including the victims, have been told when the consultation announced on 17 July will take place. The victims of contaminated blood products are still suffering while the Government continue to procrastinate on this issue.

--- Later in debate ---

[Ms Ritchie]

My hon. Friend has captured the anxiety and trauma of those affected and the need for Government compassion on this issue.

I will encapsulate the principal points. We need to know the commencement date of the consultation. It was supposed to be in autumn; we are now in autumn and we have not heard anything since the announcement on 17 July. We need the Government to detail how the £25 million will be spent and whether the various trusts will be dissolved and a lump sum made available. We need to know whether the Government will acknowledge liability and provide ongoing payments for victims and for the families who have been left with nothing following the death of a family member who contracted a virus or viruses as a result of contaminated blood products.

I say again: victims feel strongly that compensation should come not from the Department’s principal budget but from the Government’s contingency fund. Victims must have access to proper medicine, and drugs are required to be prescribed at stage 1 of the illness, before the onset of stage 2, in order to prevent liver dysfunction.

The Minister said in a statement that the Penrose report,

“together with over 5,000 documents from the period 1970-85…have already been published by Government”,

and that the Government

“have also committed to releasing all additional documents from 1986-1995 late this summer.”

When is “late this summer”? When will the documents be released?

These people, who are suffering so terribly, require truth from the Government. My constituent went to the Royal Victoria hospital in Belfast for continual reviews and was told that he had to get another test. He said, “Why do I have to get another test? Everybody knows I was born a haemophiliac, along with my two brothers.” They said, “You have hepatitis C,” and he said, “How did that happen?” It was because of blood products that were imported from the United States. That was the first he knew of it, 20 years ago. Members can imagine the trauma he felt, and that of his wife, children and wider family. Those blood products have meant that he has to attend hospital on a weekly basis and is without a job. He cannot do what he wants to do most: care for and bring up his family.

For the sake of Brian and many, many others, I urge the Minister to ensure that an abrupt close is brought to this matter, that a date for the consultation is announced, that interim moneys are made available, that full and final compensation is made available out of the Government contingency fund, and that all these terrible injustices are rectified once and for all.

[Albert Owen (in the Chair)]

Before the Minister responds, she has indicated that she would like to speak for about 12 minutes. She has a little more time, so I am sure she will be generous in taking interventions.

Contaminated Blood

Albert Owen Excerpts

Thursday 15th January 2015 Commons Chamber

[Alistair Burt]

My hon. Friend is right that many beneficiaries have expressed deep concern about the workings of the trust. The all-party group report that came out yesterday will be addressed by other colleagues. On the MacFarlane Trust in particular he should know that I share his concerns. I do not believe that that trust is salvageable or saveable, and I will speak about that later.

[Albert Owen (Ynys Môn) (Lab)]

The right hon. Gentleman read out a list of people to whom he wished to pay tribute. May I add his name to the list? I am here today because constituents came forward after he sent out the letter on behalf of the all-party group. I pay tribute to him for that. When we talk about trusts across the United Kingdom, I feel that, because this matter predates devolution, there needs to be a UK response so that the Welsh Assembly and devolved Governments are not bearing the brunt of the problem themselves. This is a UK problem, and the UK Government should look either to work with those Administrations or to take the lead.

[Alistair Burt]

There is no doubt that these matters predated devolution. As most colleagues are aware, there is a Scottish inquiry going on. Almost inevitably when it reports, it must report on things that pertain to the United Kingdom Government. I notice that the Secretary of State for Health has joined us, which illustrates the importance of this issue to all of us. He is enormously welcome, especially given the burdens that he carries. The UK dimension of this is indeed very real.

Late Stage Hepatitis C

Albert Owen Excerpts

Tuesday 6th January 2015 Westminster Hall

[Stephen Pound]

I am more than delighted to give credit to the Hepatitis C Trust, which has done exceptionally good work—I have been to a number of its meetings—but also to my hon. Friend and neighbour in Ealing. His document, “The Challenge of Hepatitis C for the South Asian Community”, will be formally launched next week. I believe that the Minister has a copy; if not, I will provide her with one almost immediately. At that launch, the issues that my hon. Friend mentioned will be widely discussed and information widely circulated. It is important to realise why there is such a high prevalence of hepatitis C in the south Asian community. Bizarrely, it is a consequence of improved health provision in that area. There are parts of the world where there is virtually no formal, structured health provision and there is no hepatitis C or, if there is, it is a minute amount, brought in externally. In south Asia, the health service is increasing its outreach: more and more people are accessing it and making use of it. However, the medical advances are not keeping pace with the advances in sterile treatment and sterile methods prevailing in the rest of the world. So, bizarrely, although there is considerable health provision in south Asia, it is not quite there yet in terms of providing a sterile environment and avoiding transmission, whereas other parts of the world have not even reached that level.

[Albert Owen (Ynys Môn) (Lab)]

My hon. Friend congratulated the Scottish Government in relation to hepatitis C—

[Stephen Pound]

Reluctantly.

[Albert Owen]

My hon. Friend did so reluctantly, but he will, I know, join me in congratulating the Welsh Government on their work on the consent issue. The serious point was made earlier about those who suffered contamination in the NHS in the ’60s, ’70s and ’80s. Does he agree with me—the Minister may want to respond to this—that we need a UK-wide approach to the matter so that compensation can be achieved for those who have been suffering for decades as a result of that contamination?

[Stephen Pound]

I enthusiastically endorse the approach of the Welsh Assembly Government on the matter, and their efforts have been widely respected and appreciated. One of the things that I seek today is precisely such an overarching, UK-wide strategy. It is important to note that the United Kingdom is the only country in Europe that is showing an increase in liver disease. All the statistics indicate that cases of liver disease, particularly hepatitis C, will continue to increase until they peak in about 2030. It is hoped that in 2030 they will tail off, partly because if we backtrack 20 or 30 years to the turn of the century, people had a bit more knowledge and understanding. One hopes that debates such as this will extend that knowledge and information outwards.

National Health Service (Amended Duties and Powers) Bill

Albert Owen Excerpts

Friday 21st November 2014 Commons Chamber

[Clive Efford]

My hon. Friend is absolutely right. We know that the Prime Minister has accepted it was a mistake, so the Government’s position on the Bill is a bit curious.

[Albert Owen (Ynys Môn) (Lab)]

Will my hon. Friend give way?

[Clive Efford]

I will, but then I will have to make some progress.

[Albert Owen]

I congratulate my hon. Friend on securing this Second Reading debate. He made an important point about the provisions applying across the United Kingdom: Wales, where the policies are different from those operating across England, would still come under the TTIP agreement, so it is important that this clause is included.